Kindred Biosciences

Kindred Biosciences is a veterinary biotechnology company, focuses on developing therapies for dogs, cats, and horses. It develops canine, feline, and equine antibodies for the treatment of diseases in companion animals. Its strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for animal companions. Their mission is to bring innovative biologics to veterinary medicine because they believe their pets deserve the same kinds of safe and effective medicines that human family members enjoy. The company was incorporated in 2012 and is based in San Francisco, California.

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q4 2019 Results - Earnings Call Transcript

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q3 2019 Results - Earnings Call Transcript

Kindred Bio (KIN) delivered earnings and revenue surprises of -11.43% and -28.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Kindred Biosciences (KIN) Reports Q3 Loss, Lags Revenue Estimates

Kindred Biosciences' (KIN) CEO Richard Chin on Q2 2019 Results - Earnings Call Transcript

Adaptimmune Therapeutics

Cloudera

Falcon Minerals Corp

Zynga

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 More Stocks Priced Under $10 With Massive Implied Upside

Kindred Biosciences'(KIN) CEO Richard Chin on Q1 2019 Results - Earnings Call Transcript

Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and -73.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Kindred Biosciences (KIN) Reports Q1 Loss, Misses Revenue Estimates

KIN earnings call for the period ending December 31, 2018.

News for Kindred Biosciences Stock (KIN)